|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **All pregnancies** | | **Subgroup 1** | | **Subgroup 2** | |
| **Variable** | **Value** | **N** | **Value** | **N1** | **Value** | **N2** |
| Hippocampal atrophy, n (%) | 15 (63) | 24 | 10 (56) | 18 | 5 (83) | 6 |
| Periventricular heterotopia, n (%) | 3 (13) | 24 | 2 (11) | 18 | 1 (17) | 6 |
| Cavernous angioma, n (%) | 2 (8) | 24 | 2 (11) | 18 | 0 | 6 |
| Parasagittal encephalomalacia, n (%) | 1 (4) | 24 | 1 (6) | 18 | 0 | 6 |
| Residual parietal angiomatous nidus after AVM removal, n (%) | 1 (4) | 24 | 1 (6) | 18 | 0 | 6 |
| Temporal cysticercosis, n (%) | 1 (4) | 24 | 1 (6) | 18 | 0 | 6 |
| Right paracentral lobula lesion (probably DNET), n (%) | 1 (4) | 24 | 1 (6) | 18 | 0 | 6 |

**Table S1: Description of types of lesional epilepsy.**

AVM = arteriovenous malformation; n = count; N = sample size.

Subgroup 1 included pregnancies occurring in patients who had no disabling seizures during pregnancy. Subgroup 2 included pregnancies occurring in patients who had disabling seizures during pregnancy.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **All pregnancies** | | **Subgroup 1** | | **Subgroup 2** | |
| **Variable** | **Value** | **N** | **Value** | **N1** | **Value** | **N2** |
| Normal genetic panel, n (%) | 5 (38) | 13 | 4 (40) | 10 | 1 (33) | 3 |
| SCN1A + POLG heterozygous VUS, n (%) | 2 (15) | 13 | 2 (20) | 10 | 0 | 3 |
| SCN2A heterozygous VUS, n (%) | 2 (15) | 13 | 2 (20) | 10 | 0 | 3 |
| SCN1A heterozygous VUS, n (%) | 1 (8) | 13 | 1 (10) | 10 | 0 | 3 |
| DEPDC5 heterozygous VUS, n (%) | 1 (8) | 13 | 1 (10) | 10 | 0 | 3 |
| ALDH7A1 heterozygous pathogenic mutation, n (%) | 1 (8) | 13 | 0 | 10 | 1 (33) | 3 |
| MTHFR homozygous pathogenic mutation, n (%) | 1 (8) | 13 | 0 | 10 | 1 (33) | 3 |

**Table S2: Description of genetic panel results.**

n = count; N = sample size, VUS = variant of unknown significance.

Subgroup 1 included pregnancies occurring in patients who had no disabling seizures during pregnancy. Subgroup 2 included pregnancies occurring in patients who had disabling seizures during pregnancy.